Related Experiment Video
Updated: Jun 4, 2025

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Exploiting NRF2-ARE pathway activation in papillary renal cell carcinoma
Silvia Angori1, Harini Lakshminarayanan1, Amir Banaei-Esfahani1
1Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.
Abstract:
Papillary renal cell carcinoma (pRCC) is the second most frequent renal cancer subtype but has no indicated targeted treatments. MET inhibition may be a treatment for MET-driven pRCC, but there is a large group of non-MET-driven pRCC without targeted therapy. Activation of NRF2-ARE pathway has been suggested to be involved in pRCC. To study the relevance of the NRF2-ARE pathway, we characterized 60 pRCCs by copy number analysis and Whole Exome Sequencing. Because stabilisation of NRF2 results in enhanced expression of NQO1, a reductase that prevents production of reactive oxygen species, protein expression of NQO1 was analysed by immunohistochemistry (IHC) from tissue microarrays (TMAs) and by enzymatic activity assay. Finally, patient-derived pRCC cells (PDCs) were applied for drug profiling with 18 NRF2-ARE pathway inhibitors. We identified MET mutations in 5%, and mutations in four genes of NRF2-ARE pathway (NFE2L2, KEAP1, CUL3 and BACH1) in 10% of 60 pRCC samples. IHC analysis of TMAs of 638 renal cancers showed the correlation of the expression of NQO1 with poor survival outcome (p < .001) and high tumour grade (p < .001) and stage (p < .001) in pRCC. NQO1 mRNA, protein levels and enzymatic activity were increased in 56% of matched pRCC tissue samples and patient-derived cells (PDCs, n = 9). Drug screening revealed that Brusatol and Convallatoxin are potential novel drugs for pRCC. Inhibition of NRF2 represents a novel therapeutic approach for MET-independent pRCC patients.
Insights
Papillary renal cell carcinoma (pRCC) lacks targeted treatments. This study reveals NRF2-ARE pathway involvement in pRCC, identifying NQO1 as a poor survival marker and potential drug targets like Brusatol for MET-independent pRCC.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Papillary renal cell carcinoma (pRCC) is the second most common kidney cancer subtype.
- Currently, pRCC lacks specific targeted therapies, especially for non-MET-driven cases.
- The NRF2-ARE pathway is implicated in pRCC development and progression.
Purpose of the Study:
- To investigate the role of the NRF2-ARE pathway in pRCC.
- To identify potential therapeutic targets for pRCC, particularly MET-independent subtypes.
Main Methods:
- Copy number analysis and Whole Exome Sequencing of 60 pRCC samples.
- Immunohistochemistry (IHC) for NQO1 expression on tissue microarrays (TMAs).
- Enzymatic activity assays and drug profiling of patient-derived pRCC cells (PDCs) with NRF2-ARE pathway inhibitors.
Main Results:
- Mutations in MET (5%) and NRF2-ARE pathway genes (10%) were identified in pRCC samples.
- Increased NQO1 expression correlated with poor survival, high tumor grade, and advanced stage in pRCC.
- NQO1 levels and activity were elevated in 56% of pRCC tissues and PDCs, with Brusatol and Convallatoxin showing promise as novel therapeutic agents.
Conclusions:
- The NRF2-ARE pathway is significantly involved in pRCC pathogenesis.
- NQO1 serves as a prognostic biomarker for poor survival in pRCC.
- Inhibiting the NRF2 pathway presents a novel therapeutic strategy for MET-independent pRCC.
More Related Videos
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
PI3K/mTOR/AKT Signaling Pathway
MAPK Signaling Cascades
Mitogens and the Cell Cycle
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...

